Jan 2026· Journal of Diabetes Research· Vol 2026· 0 citations· 36 references
Medicine
TL;DR
PDK4 and ACOT1 are identified as evolutionarily conserved metabolic hub genes associated with myocardial fibrosis in DCM, suggesting a putative “metabolism–fibrosis axis” and providing potential therapeutic targets.
Abstract
Diabetic cardiomyopathy (DCM) is a critical pathological driver of heart failure in diabetic patients, primarily characterized by progressive myocardial fibrosis. Nevertheless, the core molecular network linking upstream metabolic dysregulation to the aberrant activation of downstream cardiac fibroblasts remains largely elusive. In this study, we combined in vivo and in vitro approaches with bioinformatics analysis. A high‐fat diet‐induced mouse model of diabetic myocardial fibrosis was established, and transcriptome sequencing was performed to screen for hub genes, which were subsequently validated in two independent DCM datasets. Single‐cell RNA sequencing revealed that PDK4 and ACOT1 were upregulated in cardiac fibroblasts under pathological conditions. In vitro experiments confirmed that high glucose induced the expression of PDK4, ACOT1, and fibrotic markers in human primary cardiac fibroblasts. Molecular docking predicted a potential interaction between PDK4 and ACOT1. Collectively, our findings identify PDK4 and ACOT1 as evolutionarily conserved metabolic hub genes associated with myocardial fibrosis in DCM, suggesting a putative “metabolism–fibrosis axis” and providing potential therapeutic targets.
BACKGROUND
Myocardial fibrosis represents a critical prognostic indicator of poor outcomes in hypertrophic cardiomyopathy (HCM), frequently predisposing patients to lethal ventricular arrhythmias and progressive heart failure. However, the upstream molecular mechanisms driving cardiac fibrogenesis in HCM remain largely...
Lei Chang, Chen-Yi Gong, Zhi-Kang Wu et al.· Biochemical and Biophysical...· 0 citations
It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.
Lin Zhou, Yu Zhang, Xinxin Tan et al.· International Immunopharmaco...· 0 citations
Background: Fibrosis development in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and li...
Jessica L. Maiers, Tie-Bing Liang, Tingbo Guo et al.· Hepatology Communications· 0 citations
A novel mechanism by which ACSL4 fuels PASMC growth in PH through reshaping fatty acid metabolism and targeting the VGLL4/YAP signaling axis is uncovers.
Wei Chen, Yi-Ting Dong, Qiong Shi et al.· Vascular pharmacology· 0 citations
Secondary cardiomyopathies are a major cause of heart failure (HF) with diverse etiologies and high mortality rates. For example, over 50% of patients with end-stage liver disease develop cardiac dysfunction, clinically termed cirrhotic cardiomyopathy (CCM). While serum metabolites mediating cross-organ communica...
Cancan Yao, Yan Chen, Zhouping Lu et al.· Journal of Translational Med...· 0 citations
This protocol provides an integrated framework for identifying candidate biomarkers and molecular subtypes in DCM and identified SERPINE1, TGFB2, CYBB, and TLR2 as core genes.
Yuna Zhou· Journal of Visualized Experi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.